trending Market Intelligence /marketintelligence/en/news-insights/trending/VCHn9XtbysLKB_x3W5FfjA2 content esgSubNav
In This List

OncoMed CEO to resume duties as chairman

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


OncoMed CEO to resume duties as chairman

OncoMed Pharmaceuticals Inc. President and CEO Paul Hastings will resume his role as board chairman, effective Dec. 4.

Hastings has been on medical leave since September.

The office of the president — comprising John Lewicki, executive vice president of research and development, and Executive Vice President and CFO Sunil Patel — will continue to perform the duties of the president and CEO.